{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:51:38Z","timestamp":1791525098604,"version":"4.3.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    We fully documented the diagnostic process of three hypertrophic cardiomyopathy (HCM) cases without typical asymmetric myocardial hypertrophy, including medical histories, imaging, and laboratory tests, ultimately confirming the diagnosis through genetic testing. Case 1 presented with segmental wall motion abnormalities with thrombosis, requiring differentiation from coronary atherosclerotic heart disease; case 2 presented with restrictive hemodynamic changes that could be confused with restrictive cardiomyopathy such as amyloidosis; case 3 occurred in a pediatric setting and showed diffuse and concentric hypertrophy similar to metabolic disorders. Various imaging examinations were employed for differential diagnosis, and whole-exome sequencing identified a pathogenic MYBPC3 mutation in case 1 and pathogenic MYH7 mutations in cases 2 and 3, including a\n                    <jats:italic>de novo<\/jats:italic>\n                    variant in case 3. We provided appropriate treatment and follow-up for each case. Case 1's left ventricular ejection fraction increased to 48%, and cases 2 and 3 have not experienced worsening heart failure or malignant arrhythmic events based on an optimized drug regimen. This case series confirms the diversity of echocardiographic phenotypes in end-stage HCM, underscoring the role of multimodal imaging and genetic testing in diagnosis and differential diagnosis.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1907550","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:29:47Z","timestamp":1791523787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Atypical echocardiographic phenotype of end-stage hypertrophic cardiomyopathy: a case series"],"prefix":"10.3389","volume":"13","author":[{"given":"Xi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ultrasonography, Sixth Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, Sixth Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sixth Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sixth Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.4103\/0366-6999.157656","article-title":"Clinical characteristics and prognosis of end-stage hypertrophic cardiomyopathy","volume":"128","author":"Xiao","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12574-019-00454-9","article-title":"The role of echocardiography in management of hypertrophic cardiomyopathy","volume":"18","author":"Haland","year":"2020","journal-title":"J Echocardiogr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcmg.2025.08.019","article-title":"Feature tracking-derived global longitudinal strain enhances risk stratification for sudden cardiac death in hypertrophic cardiomyopathy","volume":"19","author":"Ma","year":"2026","journal-title":"JACC Cardiovasc Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging","volume":"5","author":"Olivotto","year":"2012","journal-title":"Circ Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e931359","DOI":"10.12659\/AJCR.931359","article-title":"Regression of systolic anterior motion in progressive hypertrophic cardiomyopathy","volume":"22","author":"Koren","year":"2021","journal-title":"Am J Case Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.108.781401","article-title":"Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy","volume":"118","author":"Maron","year":"2008","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.3390\/ijms241914845","article-title":"Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts","volume":"24","author":"Schlittler","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.123.065037","article-title":"Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy","volume":"148","author":"Rowin","year":"2023","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1161\/CIR.0000000000000938","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0735-1097(99)00492-1","article-title":"Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death","volume":"35","author":"Shirani","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.15420\/aer.2013.2.1.36","article-title":"Mimics of hypertrophic cardiomyopathy\u2014diagnostic clues to aid early identification of phenocopies","volume":"2","author":"Rajiv","year":"2013","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10741-020-10058-6","article-title":"Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment","volume":"26","author":"Pagourelias","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1136\/heart.89.10.1179","article-title":"Mutations of the \u03b2 myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis","volume":"89","author":"Woo","year":"2003","journal-title":"Heart"},{"key":"B20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/JCI116957","article-title":"Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy","volume":"93","author":"Anan","year":"1994","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","article-title":"The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"24","author":"Nag","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/s41467-019-10555-9","article-title":"\u03b2-cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity","volume":"10","author":"Adhikari","year":"2019","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","article-title":"Predicting splicing from primary sequence with deep learning","volume":"176","author":"Jaganathan","year":"2019","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1093\/nar\/15.17.7155","article-title":"RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression","volume":"15","author":"Shapiro","year":"1987","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e002905","DOI":"10.1161\/CIRCGEN.120.002905","article-title":"Cryptic splice-altering variants in MYBPC3 are a prevalent cause of hypertrophic cardiomyopathy","volume":"13","author":"Lopes","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e002368","DOI":"10.1161\/CIRCGEN.118.002368","article-title":"Key value of RNA analysis of MYBPC3 splice-site variants in hypertrophic cardiomyopathy","volume":"12","author":"Singer","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pcad.2023.04.009","article-title":"Evolution of genetic testing and gene therapy in hypertrophic cardiomyopathy","volume":"80","author":"Chiswell","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/BF02281865","article-title":"Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure","volume":"97","author":"Ko","year":"1996","journal-title":"Hum Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"691653","DOI":"10.3389\/fcvm.2021.691653","article-title":"Validation of the 2020 AHA\/ACC risk stratification for sudden cardiac death in Chinese patients with hypertrophic cardiomyopathy","volume":"8","author":"Dong","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1907550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:29:49Z","timestamp":1791523789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1907550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2026.1907550"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1907550","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1907550"}}